Tau protein in cerebrospinal fluid: a novel biomarker of the time of death?
Biochemistry
Cerebrospinal fluid
Forensic pathology
Phosphorylated tau
Post-mortem interval
Tau protein
Journal
International journal of legal medicine
ISSN: 1437-1596
Titre abrégé: Int J Legal Med
Pays: Germany
ID NLM: 9101456
Informations de publication
Date de publication:
Sep 2021
Sep 2021
Historique:
received:
13
11
2020
accepted:
02
03
2021
pubmed:
20
3
2021
medline:
28
9
2021
entrez:
19
3
2021
Statut:
ppublish
Résumé
Tau proteins are recognized biomarkers of neurodegeneration and neuronal damage in the cerebrospinal fluid (CSF). It has also been suggested that these CSF proteins could increase post-mortem due to neuronal death. The aim of this study was to investigate the changes in CSF total and phosphorylated tau (p-tau) levels in the early post-mortem interval (PMI), to determine whether these proteins could be relevant biomarkers of time since death. Tau and p-tau levels were measured by ELISA in lumbar and cisternal CSF samples from 82 corpses (46 men, 36 women, mean age: 72.4 ± 15.2 years) with a PMI < 12 h. Forty-eight of them were considered neurologically healthy at the time of death. Rectal and tympanic temperatures were also measured in 37 individuals, and two validated temperature-based methods of PMI estimation were applied (Henssge's nomogram and Baccino's method). CSF tau and p-tau levels were significantly increased, with respective median values of 3315 pg/mL and 68.5 pg/mL in the whole cohort, while lower but still increased levels were observed in neurologically healthy patients. Sub-occipital punctures systematically provided higher tau and p-tau values (p < 0.0001). Despite a great inter-individual variability, the concentrations of both biomarkers were positively correlated with the early PMI, with the highest correlation for cisternal p-tau (r = 0.50, p < 0.0001 in the whole cohort; r = 0.58, p = 0.0003 in the neurologically healthy patients). Higher levels of CSF biomarkers were observed for PMI > 6 h versus PMI ≤ 6 h, the discriminatory power of the biomarkers being higher in the subgroup of neurologically healthy patients. Based on cut-off values obtained by ROC curve analysis, the CSF biomarkers could rectify or adjust the time interval provided by the temperature-based methods in a significant number of cases. A predictive model combining tympanic temperature and cisternal tau values was found to be particularly accurate to assign individuals according to their PMI (≤ or > 6 h), with a Se of 83% and a Sp of 100% (AUC = 0.95). Our findings suggest that CSF tau and p-tau proteins could serve as potential biomarkers of time since death, in association with tympanic temperature. The practical applicability of such an integrated approach has to be assessed by further studies.
Sections du résumé
BACKGROUND
BACKGROUND
Tau proteins are recognized biomarkers of neurodegeneration and neuronal damage in the cerebrospinal fluid (CSF). It has also been suggested that these CSF proteins could increase post-mortem due to neuronal death. The aim of this study was to investigate the changes in CSF total and phosphorylated tau (p-tau) levels in the early post-mortem interval (PMI), to determine whether these proteins could be relevant biomarkers of time since death.
METHODS
METHODS
Tau and p-tau levels were measured by ELISA in lumbar and cisternal CSF samples from 82 corpses (46 men, 36 women, mean age: 72.4 ± 15.2 years) with a PMI < 12 h. Forty-eight of them were considered neurologically healthy at the time of death. Rectal and tympanic temperatures were also measured in 37 individuals, and two validated temperature-based methods of PMI estimation were applied (Henssge's nomogram and Baccino's method).
RESULTS
RESULTS
CSF tau and p-tau levels were significantly increased, with respective median values of 3315 pg/mL and 68.5 pg/mL in the whole cohort, while lower but still increased levels were observed in neurologically healthy patients. Sub-occipital punctures systematically provided higher tau and p-tau values (p < 0.0001). Despite a great inter-individual variability, the concentrations of both biomarkers were positively correlated with the early PMI, with the highest correlation for cisternal p-tau (r = 0.50, p < 0.0001 in the whole cohort; r = 0.58, p = 0.0003 in the neurologically healthy patients). Higher levels of CSF biomarkers were observed for PMI > 6 h versus PMI ≤ 6 h, the discriminatory power of the biomarkers being higher in the subgroup of neurologically healthy patients. Based on cut-off values obtained by ROC curve analysis, the CSF biomarkers could rectify or adjust the time interval provided by the temperature-based methods in a significant number of cases. A predictive model combining tympanic temperature and cisternal tau values was found to be particularly accurate to assign individuals according to their PMI (≤ or > 6 h), with a Se of 83% and a Sp of 100% (AUC = 0.95).
CONCLUSION
CONCLUSIONS
Our findings suggest that CSF tau and p-tau proteins could serve as potential biomarkers of time since death, in association with tympanic temperature. The practical applicability of such an integrated approach has to be assessed by further studies.
Identifiants
pubmed: 33740116
doi: 10.1007/s00414-021-02558-3
pii: 10.1007/s00414-021-02558-3
doi:
Substances chimiques
Biomarkers
0
MAPT protein, human
0
tau Proteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2081-2089Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Madea B (2015) Estimation of the time since death, 3rd edn. CRC Press, Boca Raton
doi: 10.1201/b19276
Madea B (2016) Methods for determining time of death. Forensic Sci Med Pathol 12:451–485. https://doi.org/10.1007/s12024-016-9776-y
doi: 10.1007/s12024-016-9776-y
pubmed: 27259559
Saukko PJ, Knight B (2015) Knight’s forensic pathology, 4th edn. CRC Press, Boca Raton
doi: 10.1201/b13266
Palmiere C, Mangin P (2012) Postmortem chemistry update part I. Int J Legal Med 126:187–198. https://doi.org/10.1007/s00414-011-0625-y
doi: 10.1007/s00414-011-0625-y
pubmed: 21947676
Palmiere C, Mangin P (2012) Postmortem chemistry update part II. Int J Legal Med 126:199–215. https://doi.org/10.1007/s00414-011-0614-1
doi: 10.1007/s00414-011-0614-1
pubmed: 21984165
Madea B (2005) Is there recent progress in the estimation of the postmortem interval by means of thanatochemistry? Forensic Sci Int 151:139–149. https://doi.org/10.1016/j.forsciint.2005.01.013
doi: 10.1016/j.forsciint.2005.01.013
pubmed: 15939145
Andreasen N, Blennow K (2005) CSF biomarkers for mild cognitive impairment and early Alzheimer’s disease. Clin Neurol Neurosurg 107:165–173. https://doi.org/10.1016/j.clineuro.2004.10.011
doi: 10.1016/j.clineuro.2004.10.011
pubmed: 15823670
Wang Y, Mandelkow E (2016) Tau in physiology and pathology. Nat Rev Neurosci 17:5–21. https://doi.org/10.1038/nrn.2015.1
doi: 10.1038/nrn.2015.1
pubmed: 26631930
Sjögren M, Vanderstichele H, Agren H et al (2001) Tau and Abeta42 in cerebrospinal fluid from healthy adults 21–93 years of age: establishment of reference values. Clin Chem 47:1776–1781
doi: 10.1093/clinchem/47.10.1776
Gabelle A, Dumurgier J, Vercruysse O et al (2013) Impact of the 2008–2012 French Alzheimer Plan on the use of cerebrospinal fluid biomarkers in research memory center: the PLM study. J Alzheimers Dis 34:297–305. https://doi.org/10.3233/JAD-121549
doi: 10.3233/JAD-121549
pubmed: 23186986
Hesse C, Rosengren L, Andreasen N et al (2001) Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke. Neurosci Lett 297:187–190. https://doi.org/10.1016/s0304-3940(00)01697-9
doi: 10.1016/s0304-3940(00)01697-9
pubmed: 11137759
De Vos A, Bjerke M, Brouns R et al (2017) Neurogranin and tau in cerebrospinal fluid and plasma of patients with acute ischemic stroke. BMC Neurol 17:170. https://doi.org/10.1186/s12883-017-0945-8
doi: 10.1186/s12883-017-0945-8
pubmed: 28854881
pmcid: 5577791
Kapaki E, Kilidireas K, Paraskevas GP et al (2001) Highly increased CSF tau protein and decreased beta-amyloid (1–42) in sporadic CJD: a discrimination from Alzheimer’s disease? J Neurol Neurosurg Psychiatry 71:401–403. https://doi.org/10.1136/jnnp.71.3.401
doi: 10.1136/jnnp.71.3.401
pubmed: 11511720
pmcid: 1737566
Arai H, Terajima M, Miura M et al (1995) Tau in cerebrospinal fluid: a potential diagnostic marker in Alzheimer’s disease. Ann Neurol 38:649–652. https://doi.org/10.1002/ana.410380414
doi: 10.1002/ana.410380414
pubmed: 7574462
Zetterberg H, Hietala MA, Jonsson M et al (2006) Neurochemical aftermath of amateur boxing. Arch Neurol 63:1277–1280. https://doi.org/10.1001/archneur.63.9.1277
doi: 10.1001/archneur.63.9.1277
pubmed: 16966505
Buerger K, Ewers M, Pirttilä T et al (2006) CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer’s disease. Brain 129:3035–3041. https://doi.org/10.1093/brain/awl269
doi: 10.1093/brain/awl269
pubmed: 17012293
Morihara T, Kudo T, Ikura Y et al (1998) Increased tau protein level in postmortem cerebrospinal fluid. Psychiatry Clin Neurosci 52:107–110. https://doi.org/10.1111/j.1440-1819.1998.tb00981.x
doi: 10.1111/j.1440-1819.1998.tb00981.x
pubmed: 9682942
Kuhn M, Wing J, Weston S et al (2020) Caret: classification and regression training. R package version 6.0–86. https://CRAN.R-project.org/package=caret
Reiber H (2001) Dynamics of brain-derived proteins in cerebrospinal fluid. Clin Chim Acta 310:173–186
doi: 10.1016/S0009-8981(01)00573-3
Winblad B, Amouyel P, Andrieu S et al (2016) Defeating Alzheimer’s disease and other dementias: a priority for European science and society. Lancet Neurol 15:455–532. https://doi.org/10.1016/S1474-4422(16)00062-4
doi: 10.1016/S1474-4422(16)00062-4
pubmed: 26987701
Delacourte A, Sergeant N, Wattez A et al (2002) Tau aggregation in the hippocampal formation: an ageing or a pathological process? Exp Gerontol 37:1291–1296. https://doi.org/10.1016/s0531-5565(02)00141-9
doi: 10.1016/s0531-5565(02)00141-9
pubmed: 12470843
Dreier JP, Major S, Foreman B et al (2018) Terminal spreading depolarization and electrical silence in death of human cerebral cortex. Ann Neurol 83:295–310. https://doi.org/10.1002/ana.25147
doi: 10.1002/ana.25147
pubmed: 29331091
pmcid: 5901399
Vrselja Z, Daniele SG, Silbereis J et al (2019) Restoration of brain circulation and cellular functions hours post-mortem. Nature 568:336–343. https://doi.org/10.1038/s41586-019-1099-1
doi: 10.1038/s41586-019-1099-1
pubmed: 30996318
pmcid: 6844189
Peyron P-A, Lehmann S, Delaby C et al (2019) Biochemical markers of time since death in cerebrospinal fluid: a first step towards “Forensomics.” Crit Rev Clin Lab Sci 56:274–286. https://doi.org/10.1080/10408363.2019.1619158
doi: 10.1080/10408363.2019.1619158
pubmed: 31088325
Meurs J, Krap T, Duijst W (2019) Evaluation of postmortem biochemical markers: completeness of data and assessment of implication in the field. Sci Justice 59:177–180. https://doi.org/10.1016/j.scijus.2018.09.002
doi: 10.1016/j.scijus.2018.09.002
pubmed: 30798866
Blomberg M, Jensen M, Basun H et al (2001) Cerebrospinal fluid tau levels increase with age in healthy individuals. DEM 12:127–132. https://doi.org/10.1159/000051246
doi: 10.1159/000051246
Nokes LD, Hicks B, Knight BH (1985) The post-mortem temperature plateau–fact or fiction? Med Sci Law 25:263–264. https://doi.org/10.1177/002580248502500406
doi: 10.1177/002580248502500406
pubmed: 4068955